Pain News and Research

Latest Pain News and Research

Study evaluates OCP treatment to prevent endometrioma recurrence

Ovarian endometriomas, better known as ovarian 'chocolate' cysts for the brown liquid they contain, can be easily removed by surgery. However, recurrence is common, which can cause ongoing pain and complications. A study evaluated for Faculty of 1000 suggests a simple and effective remedy - the oral contraceptive pill.

31 Mar 2010

QRxPharma initiates Phase 1 trial for evaluating PK profiles of morphine, oxycodone CR formulations

QRxPharma announced today initiation of the Company's first Phase 1 trial to evaluate the pharmacokinetic (PK) profiles of experimental controlled-release (CR) morphine and oxycodone formulations that will be incorporated into MoxDuo®CR. MoxDuo®CR contains a fixed 3:2 morphine:oxycodone combination and is intended to be dosed twice daily in patients experiencing chronic pain, an approximately US$7 billion dollar market worldwide.

31 Mar 2010

Asclera injection receives FDA approval

The U.S. Food and Drug Administration today approved Asclera (polidocanol) injection for the treatment of small types of abnormally swollen or twisted veins called varicose veins.

31 Mar 2010

Facts and treatment options for endometriosis

One out of every two women struggling to conceive may suffer from endometriosis - the leading cause of infertility - according to research from Camran Nezhat, M.D., gynecologist at El Camino Hospital, the hospital of the Silicon Valley.

31 Mar 2010

Multi-center clinical trial of MyoSure Hysteroscopic Tissue Removal System initiated

Interlace Medical, Inc., today announced that it has initiated a multi-center clinical trial of the MyoSure Hysteroscopic Tissue Removal System. The purpose of this study is to demonstrate that women experience minimal to no pain or discomfort during a MyoSure procedure, when given a mild oral sedative together with a local anesthetic injected into the cervix.

30 Mar 2010

Ascent Therapeutics is now Anchor Therapeutics

Ascent Therapeutics announced today that it has adopted a new name — Anchor Therapeutics. Anchor Therapeutics reflects the Company's core technology and its commitment to building solid, dependable value for patients, partners and investors via its proprietary platform technology.

30 Mar 2010

Euthanasia: Defining actions and terms, and promoting honest debate needed

It is time to discard the word euthanasia because it mixes ideas and values that confuses the debate about dying, states an editorial in CMAJ (Canadian Medical Association Journal)

30 Mar 2010

Research: Having large number of supportive relatives increases fear of dying among elderly

Having a large number of supportive relatives increases the fear of dying among the elderly from ethnic minority groups, suggests research in Postgraduate Medical Journal.

30 Mar 2010

ASA encourages spreading awareness about Doctors Day 2010

The American Society of Anesthesiologists joins communities across the United States today to recognize Doctors Day 2010, a day with a special tie to anesthesiology.

30 Mar 2010

Enrollment complete in Paradigm Spine's comparative study of coflex interlaminar technology

Paradigm Spine, LLC, a developer of innovative non-fusion and fusion spinal implant solutions, announced today that it has completed patient enrollment in an Investigational Device Exemption pivotal clinical study comparing the coflex® interlaminar technology to instrumented posterolateral fusion in the surgical treatment of spinal stenosis.

30 Mar 2010

Enobia Pharma unveils findings from first HPP self-reported patient survey at ACMG 2010

Enobia Pharma Inc. unveiled findings from the first hypophosphatasia self-reported patient survey intended to evaluate the burden of illness associated with HPP at the 2010 American College of Medical Genetics Annual Clinical Genetics Meeting.

30 Mar 2010

Alcon acquires right to market DUREZOL ophthalmic corticosteroid in U.S.

Alcon, the world's leader in eye care, announced today that it received regulatory approval and finalized the acquisition of the rights in the United States for DUREZOL™ emulsion and the global rights, excluding Latin America, for ZYCLORIN™ from Sirion Therapeutics, Inc.

30 Mar 2010

4 kg liver tumor removed from 60 year old Nigerian

A team of doctors led by Dr Ramcharan Thiagarajan, Consultant Surgical Gastroenterology & Hepato Pancreatic Biliary Surgery, Fortis Hospitals, Bangalore (formerly Wockhardt Hospitals) recently performed a high risk surgery on a 60 year old Nigerian to remove a perilous tumor weighing 4 kilos surrounding his liver.

29 Mar 2010

Addiction to high calorie fat rich food: likened to cocaine and heroin addiction

In a new research our worst fears are confirmed – fatty, fried and fattening foods are addictive. The addiction with these delicious ‘yummies’ may be as potent as that with cocaine or heroin. The study was conducted on experimental animals, rats in this case. When fed with fatty foods in great quantities these rats showed a compulsive need to eat.

29 Mar 2010

Cortex signs agreement to sell certain AMPAKINE compounds to Biovail

Cortex Pharmaceuticals, Inc. announced that it has entered into an agreement with Biovail Laboratories International SRL in which Biovail acquired certain AMPAKINE compounds and the rights to the patent filing for respiratory depression and vaso-occlusive crises associated with sickle cell disease.

29 Mar 2010

FDA: Outbreak of campylobacteriosis linked to drinking raw milk

The U.S. Food and Drug Administration, along with several state agencies, is alerting consumers to an outbreak of campylobacteriosis associated with drinking raw milk. At least 12 confirmed illnesses have been recently reported in Michigan. Symptoms of campylobacteriosis include diarrhea, abdominal pain and fever.

27 Mar 2010

IQWiG: Not all forms of massage therapy proven to help against low back pain

Most people have experienced back pain - and many hope that massage will relieve it. But not all forms of massage have been scientifically proven to help against low back pain. That is what the German Institute for Quality and Efficiency in Health Care pointed out in information published on informedhealthonline.org today.

27 Mar 2010

WinRho SDF for ITP: Cangene announces new safety information

Cangene Corporation, in consultation with Health Canada, is informing Canadian patients and healthcare professionals of important new safety information concerning the use of WinRho SDF (Rho (D) Immune Globulin (Human)) for the treatment of immune thrombocytopenic purpura, also called immune thrombocytopenia, or ITP. WinRho SDF belongs to a group of biological medicines derived from human plasma known as immunoglobulins. It is administered in hospitals by infusion through the veins.

27 Mar 2010

Health Canada accepts Cipher Pharmaceuticals' NDS for CIP-TRAMADOL ER

Cipher Pharmaceuticals Inc. today announced that its New Drug Submission (NDS) to Health Canada for CIP-TRAMADOL ER, its extended-release formulation of tramadol, has been accepted for review. The Company expects the review to be completed by early 2011.

26 Mar 2010

Inflamed tissues linked to increased production of protein involved in pain signaling

Using a novel animal model to study craniofacial pain, researchers at Oregon Health & Science University's School of Dentistry have discovered that when tissues are inflamed, the nerve cells carrying pain information from the head to the brain produce in large quantities a protein involved in pain signaling.

26 Mar 2010